Cefazolin
|
|
Cefazolin ??
- ???
- 198-200 C
- ??
- 2.01±0.1 g/cm3(Predicted)
- ?? ??
- Hygroscopic, -20°C Freezer, Under inert atmosphere
- ???
- DMSO(?? ???), ???(?? ??, ??)
- ?? ?? (pKa)
- pKa 2.15 (Uncertain)
- ??? ??
- Solid
- ??
- ???? ?????
- ???
- ???
- ?? ??
- ???(???)
- InChI
- 1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1
- InChIKey
- MLYYVTUWGNIJIB-BXKDBHETSA-N
- SMILES
- [s]1c(nnc1C)SCC2=C(N3[C@H](SC2)[C@@H](C3=O)NC(=O)C[n]4nnnc4)C(=O)O
- CAS ??????
- 25953-19-9(CAS DataBase Reference)
??
- ?? ? ?? ??
- ?? ? ???? ?? (GHS)
| ??? ?? | Xn | ||
|---|---|---|---|
| ?? ???? ?? | 20/21/22-36/37/38 | ||
| ????? | 26-36 | ||
| WGK ?? | 3 | ||
| HS ?? | 2941906000 | ||
| ???? ??? | 11 - Combustible Solids | ||
| Hazard Classifications | Resp. Sens. 1 Skin Sens. 1 |
||
| ?? ?? ??? | 25953-19-9(Hazardous Substances Data) | ||
| ?? | mouse,LD50,intramuscular,4gm/kg (4000mg/kg),Byoin Yakugaku. Hospital Pharmacology. Vol. 3, Pg. 220, 1978. | ||
| ???? ?? | KE-25357 |
| ????(GHS): |
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ?? ?: | Danger | |||||||||||||||||||||
| ??·?? ??: |
|
|||||||||||||||||||||
| ??????: |
|
Cefazolin C??? ??, ??, ??
??
Cefazolin has the natural acetyl side chain at C-3 replaced by a thio-linked thiadiazole ring. Although this group is an activating leaving group, the moiety is not subject to the inactivating host hydrolysis reaction that characterizes cephapirin. At C-7, it possesses a tetrazoylmethylene unit. Cefazolin is less irritating on injection than its cohort in this generation of drugs and has a longer half-life than cephapirin. Its dosing should be reduced in the presence of renal impairment. It is comparatively unstable and should be protected from heat and light.??? ??
needles??
Cefazolin is an antibacterial compound derived from 7-amino-cephalosporanic acid.??
ChEBI: A cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.Antimicrobial activity
Enterobacter, Klebsiella, Providencia, Serratia spp. and Pr. vulgaris are all resistant. B. fragilis is resistant, but other anaerobes are susceptible.Pharmacokinetics
DistributionThe volume of distribution is the smallest of the cephalosporins in group 1, perhaps an indication of relative confinement to the plasma space. It crosses inflamed synovial membranes, but the levels achieved are well below those of the simultaneous serum levels and entry to the CSF is poor. In patients receiving 10 mg/kg by intravenous bolus, mean concentrations in cancellous bone were 3.0 mg/kg when the mean serum concentration was 33 mg/L, giving a bone:serum ratio of 0.09. Some crosses the placenta, but the concentrations found in the fetus and membranes are low.
Metabolism and excretion
It is not metabolized. Around 60% of the dose is excreted in the urine within the first 6 h, producing concentrations in excess of 1 g/L. Excretion is depressed by probenecid. The renal clearance is around 65 mL/min and declines in renal failure, when the half-life may rise to 40 h, although levels in the urine sufficient to inhibit most urinary pathogens are still found. It is moderately well removed by hemodialysis and less well by peritoneal dialysis.
Levels sufficient to inhibit a number of enteric organisms likely to infect the biliary tract are found in T-tube bile (17–31 mg/L after a 1 g intravenous dose), but this is principally due to the high serum levels of the drug and the total amounts excreted via the bile are small.
Clinical Use
Cefazolin has been widely used in surgical prophylaxis, especially in biliary tract (because of the moderately high concentrations achieved in bile), orthopedic, cardiac and gynecological surgery.???
Side effects are those common to other cephalosporins ,including rare bleeding disorders and encephalopathy in patients in whom impaired excretion or direct instillation leads to very high CSF levels. Neutropenia has been described and hypoprothrombinemic bleeding has been attributed to the side chain.Cefazolin ?? ?? ? ???
???
1-??-1H-????-5-??
5-??-1,3,4-?????-2-??
1H-????-1-????
7-(5-???-5-?????????)???????
1H-????-1-??????
??????
5-??-1,3-?????????
7-??????????
??????(??)
?? ??
Cefazolin ?? ??
???( 245)?? ??
| ??? | ?? | ??? | ?? | ?? ? | ?? |
|---|---|---|---|---|---|
| Shaanxi Xianhe Biotech Co., Ltd | +86-17709210191; +8617709210191 |
Jerry@xhobio.com | China | 906 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21586 | 55 |
| Xiamen AmoyChem Co., Ltd | +86-86-5926051114 +8615060885618 |
sales@amoychem.com | China | 6366 | 58 |
| HubeiwidelychemicaltechnologyCo.,Ltd | 18627774460 |
faith@widelychemical.com | CHINA | 742 | 58 |
| BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19936 | 58 |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 |
sales@conier.com | China | 49979 | 58 |
| career henan chemical co | +86-0371-86658258 +8613203830695 |
factory@coreychem.com | China | 29792 | 58 |
| Antai Fine Chemical Technology Co.,Limited | 18503026267 |
info@antaichem.com | CHINA | 9636 | 58 |
| SIMAGCHEM CORP | +86-5922680277 +86-13806087780 |
sale@simagchem.com | China | 17346 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 |
marketing@targetmol.com | United States | 32466 | 58 |
Cefazolin ?? ??:
????? 3-??-1-??-2-????-5-? ?? ???? (2B) ?????? ???? ?? ???? ????? ??? ??????? ?????? 5-??-1,3,4-?????-2-?? ??????? ??????? 7-???-3-?????-3-??- 4-??? p-????????? ????
7-Amino-3-[(5-methyl-1,3,4-thiadiazol-2-ylthio)methyl]-3-cephem-4-carboxylic Acid
Naphazoline hydrochloride
2,1,3-Benzothiadiazole
Oxymetazoline




